News
BLRX
2.730
-7.14%
-0.210
BioLine RX Cut to Hold From Buy by Jones Trading
Dow Jones · 2d ago
Jones Trading Downgrades BioLine Rx to Hold
Benzinga · 2d ago
BioLineRx downgraded to Hold from Buy at JonesResearch
TipRanks · 2d ago
JonesTrading downgrades Bioline RX Ltd Sponsored ADR (BLRX) to a Hold
TipRanks · 2d ago
BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress
TipRanks · 3d ago
BioLineRx Earnings Call: Strategic Shifts and Growth
TipRanks · 3d ago
BioLine RX Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 3d ago
BioLine RX Price Target Raised to $26.00/Share From $9.00 by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Maintains Buy on BioLine Rx, Raises Price Target to $26
Benzinga · 3d ago
BIOLINE RX LTD <BLRX.O>: H.C. WAINWRIGHT ADJUSTS TARGET PRICE TO $26 FROM $9 TO REFLECT 1-FOR-40 REVERSE STOCK SPLIT
Reuters · 4d ago
BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split
TipRanks · 4d ago
BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements
TipRanks · 4d ago
Options Volatility and Implied Earnings Moves Today, March 31, 2025
TipRanks · 4d ago
BioLineRx GAAP EPS of -$0.01, revenue of $28.94M
Seeking Alpha · 4d ago
Options Volatility and Implied Earnings Moves This Week, March 31 – April 03, 2025
TipRanks · 4d ago
BIOLINE RX LTD - RAISES $19 MLN, REDUCES OPERATING EXPENSES BY 70%, EXTENDING CASH RUNWAY THROUGH H2 2026
Reuters · 4d ago
Weekly Report: what happened at BLRX last week (0324-0328)?
Weekly Report · 4d ago
Earnings Scheduled For March 31, 2025
Benzinga · 4d ago
Pre-Market Earnings Report for March 31, 2025 : PVLA, LIEN, WPRT, FTCI, PRPH, BLRX, WKHS, BCLI, LMFA, IMCC
NASDAQ · 6d ago
BioLineRx Q4 2024 Earnings Preview
Seeking Alpha · 6d ago
More
Webull provides a variety of real-time BLRX stock news. You can receive the latest news about Biolinerx through multiple platforms. This information may help you make smarter investment decisions.
About BLRX
More
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.